nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—prostate cancer	0.25	1	CbGaD
Tadalafil—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0775	0.207	CbGbCtD
Tadalafil—CYP3A4—Bicalutamide—prostate cancer	0.0407	0.109	CbGbCtD
Tadalafil—CYP3A4—Estramustine—prostate cancer	0.0378	0.101	CbGbCtD
Tadalafil—CYP3A4—Flutamide—prostate cancer	0.0337	0.09	CbGbCtD
Tadalafil—CYP3A4—Abiraterone—prostate cancer	0.0337	0.09	CbGbCtD
Tadalafil—CYP3A4—Cabazitaxel—prostate cancer	0.0249	0.0666	CbGbCtD
Tadalafil—CYP3A4—Estrone—prostate cancer	0.0244	0.0651	CbGbCtD
Tadalafil—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0217	0.058	CbGbCtD
Tadalafil—PDE5A—penis—prostate cancer	0.0179	0.282	CbGeAlD
Tadalafil—CYP3A4—Conjugated Estrogens—prostate cancer	0.0159	0.0426	CbGbCtD
Tadalafil—CYP3A4—Mitoxantrone—prostate cancer	0.0145	0.0387	CbGbCtD
Tadalafil—CYP3A4—Estradiol—prostate cancer	0.014	0.0374	CbGbCtD
Tadalafil—CYP3A4—Prednisone—prostate cancer	0.012	0.0321	CbGbCtD
Tadalafil—PDE11A—prostate gland—prostate cancer	0.0112	0.177	CbGeAlD
Tadalafil—CYP3A4—Etoposide—prostate cancer	0.00914	0.0244	CbGbCtD
Tadalafil—CYP3A4—Docetaxel—prostate cancer	0.00836	0.0223	CbGbCtD
Tadalafil—PDE11A—epithelium—prostate cancer	0.00826	0.13	CbGeAlD
Tadalafil—CYP3A4—Doxorubicin—prostate cancer	0.00624	0.0166	CbGbCtD
Tadalafil—PDE11A—testis—prostate cancer	0.00495	0.0781	CbGeAlD
Tadalafil—PDE5A—prostate gland—prostate cancer	0.00428	0.0674	CbGeAlD
Tadalafil—CYP3A4—urine—prostate cancer	0.00371	0.0586	CbGeAlD
Tadalafil—PDE5A—epithelium—prostate cancer	0.00314	0.0495	CbGeAlD
Tadalafil—PDE5A—renal system—prostate cancer	0.00292	0.046	CbGeAlD
Tadalafil—PDE5A—urethra—prostate cancer	0.00286	0.0451	CbGeAlD
Tadalafil—PDE5A—testis—prostate cancer	0.00188	0.0297	CbGeAlD
Tadalafil—PDE5A—lymph node—prostate cancer	0.00137	0.0215	CbGeAlD
Tadalafil—CYP3A4—renal system—prostate cancer	0.000909	0.0143	CbGeAlD
Tadalafil—Infestation NOS—Doxorubicin—prostate cancer	6.77e-05	0.000281	CcSEcCtD
Tadalafil—Infestation—Doxorubicin—prostate cancer	6.77e-05	0.000281	CcSEcCtD
Tadalafil—Dermatitis—Estradiol—prostate cancer	6.76e-05	0.000281	CcSEcCtD
Tadalafil—Tachycardia—Docetaxel—prostate cancer	6.75e-05	0.00028	CcSEcCtD
Tadalafil—Headache—Estradiol—prostate cancer	6.72e-05	0.000279	CcSEcCtD
Tadalafil—Skin disorder—Docetaxel—prostate cancer	6.72e-05	0.000279	CcSEcCtD
Tadalafil—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	6.71e-05	0.000279	CcSEcCtD
Tadalafil—Oedema—Capecitabine—prostate cancer	6.69e-05	0.000278	CcSEcCtD
Tadalafil—Angioedema—Prednisone—prostate cancer	6.68e-05	0.000277	CcSEcCtD
Tadalafil—Renal failure—Doxorubicin—prostate cancer	6.65e-05	0.000276	CcSEcCtD
Tadalafil—Infection—Capecitabine—prostate cancer	6.65e-05	0.000276	CcSEcCtD
Tadalafil—Urticaria—Etoposide—prostate cancer	6.61e-05	0.000275	CcSEcCtD
Tadalafil—Haemoglobin—Epirubicin—prostate cancer	6.6e-05	0.000274	CcSEcCtD
Tadalafil—Shock—Capecitabine—prostate cancer	6.59e-05	0.000274	CcSEcCtD
Tadalafil—Rhinitis—Epirubicin—prostate cancer	6.58e-05	0.000273	CcSEcCtD
Tadalafil—Abdominal pain—Etoposide—prostate cancer	6.58e-05	0.000273	CcSEcCtD
Tadalafil—Urinary tract infection—Doxorubicin—prostate cancer	6.58e-05	0.000273	CcSEcCtD
Tadalafil—Conjunctivitis—Doxorubicin—prostate cancer	6.58e-05	0.000273	CcSEcCtD
Tadalafil—Nervous system disorder—Capecitabine—prostate cancer	6.56e-05	0.000273	CcSEcCtD
Tadalafil—Vertigo—Prednisone—prostate cancer	6.56e-05	0.000273	CcSEcCtD
Tadalafil—Haemorrhage—Epirubicin—prostate cancer	6.56e-05	0.000273	CcSEcCtD
Tadalafil—Syncope—Prednisone—prostate cancer	6.55e-05	0.000272	CcSEcCtD
Tadalafil—Tachycardia—Capecitabine—prostate cancer	6.53e-05	0.000271	CcSEcCtD
Tadalafil—Hypoaesthesia—Epirubicin—prostate cancer	6.53e-05	0.000271	CcSEcCtD
Tadalafil—Pharyngitis—Epirubicin—prostate cancer	6.51e-05	0.000271	CcSEcCtD
Tadalafil—Skin disorder—Capecitabine—prostate cancer	6.5e-05	0.00027	CcSEcCtD
Tadalafil—Sweating—Doxorubicin—prostate cancer	6.49e-05	0.000269	CcSEcCtD
Tadalafil—Urinary tract disorder—Epirubicin—prostate cancer	6.48e-05	0.000269	CcSEcCtD
Tadalafil—Hyperhidrosis—Capecitabine—prostate cancer	6.47e-05	0.000269	CcSEcCtD
Tadalafil—Oedema peripheral—Epirubicin—prostate cancer	6.47e-05	0.000269	CcSEcCtD
Tadalafil—Hypotension—Docetaxel—prostate cancer	6.46e-05	0.000268	CcSEcCtD
Tadalafil—Haematuria—Doxorubicin—prostate cancer	6.45e-05	0.000268	CcSEcCtD
Tadalafil—Connective tissue disorder—Epirubicin—prostate cancer	6.45e-05	0.000268	CcSEcCtD
Tadalafil—Urethral disorder—Epirubicin—prostate cancer	6.43e-05	0.000267	CcSEcCtD
Tadalafil—Loss of consciousness—Prednisone—prostate cancer	6.42e-05	0.000267	CcSEcCtD
Tadalafil—Epistaxis—Doxorubicin—prostate cancer	6.38e-05	0.000265	CcSEcCtD
Tadalafil—Nausea—Estradiol—prostate cancer	6.38e-05	0.000265	CcSEcCtD
Tadalafil—Vomiting—Mitoxantrone—prostate cancer	6.36e-05	0.000264	CcSEcCtD
Tadalafil—Convulsion—Prednisone—prostate cancer	6.33e-05	0.000263	CcSEcCtD
Tadalafil—Hypertension—Prednisone—prostate cancer	6.31e-05	0.000262	CcSEcCtD
Tadalafil—Rash—Mitoxantrone—prostate cancer	6.31e-05	0.000262	CcSEcCtD
Tadalafil—Dermatitis—Mitoxantrone—prostate cancer	6.3e-05	0.000262	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.3e-05	0.000262	CcSEcCtD
Tadalafil—Headache—Mitoxantrone—prostate cancer	6.27e-05	0.00026	CcSEcCtD
Tadalafil—Hypotension—Capecitabine—prostate cancer	6.26e-05	0.00026	CcSEcCtD
Tadalafil—Insomnia—Docetaxel—prostate cancer	6.25e-05	0.00026	CcSEcCtD
Tadalafil—Myalgia—Prednisone—prostate cancer	6.22e-05	0.000258	CcSEcCtD
Tadalafil—Arthralgia—Prednisone—prostate cancer	6.22e-05	0.000258	CcSEcCtD
Tadalafil—Paraesthesia—Docetaxel—prostate cancer	6.21e-05	0.000258	CcSEcCtD
Tadalafil—Erythema multiforme—Epirubicin—prostate cancer	6.21e-05	0.000258	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.18e-05	0.000257	CcSEcCtD
Tadalafil—Dyspnoea—Docetaxel—prostate cancer	6.16e-05	0.000256	CcSEcCtD
Tadalafil—Somnolence—Docetaxel—prostate cancer	6.15e-05	0.000255	CcSEcCtD
Tadalafil—Discomfort—Prednisone—prostate cancer	6.15e-05	0.000255	CcSEcCtD
Tadalafil—Eye disorder—Epirubicin—prostate cancer	6.13e-05	0.000255	CcSEcCtD
Tadalafil—Hypersensitivity—Etoposide—prostate cancer	6.13e-05	0.000255	CcSEcCtD
Tadalafil—Tinnitus—Epirubicin—prostate cancer	6.12e-05	0.000254	CcSEcCtD
Tadalafil—Haemoglobin—Doxorubicin—prostate cancer	6.1e-05	0.000254	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.1e-05	0.000253	CcSEcCtD
Tadalafil—Cardiac disorder—Epirubicin—prostate cancer	6.09e-05	0.000253	CcSEcCtD
Tadalafil—Flushing—Epirubicin—prostate cancer	6.09e-05	0.000253	CcSEcCtD
Tadalafil—Rhinitis—Doxorubicin—prostate cancer	6.09e-05	0.000253	CcSEcCtD
Tadalafil—Dyspepsia—Docetaxel—prostate cancer	6.09e-05	0.000253	CcSEcCtD
Tadalafil—Haemorrhage—Doxorubicin—prostate cancer	6.07e-05	0.000252	CcSEcCtD
Tadalafil—Insomnia—Capecitabine—prostate cancer	6.05e-05	0.000252	CcSEcCtD
Tadalafil—Hypoaesthesia—Doxorubicin—prostate cancer	6.04e-05	0.000251	CcSEcCtD
Tadalafil—Pharyngitis—Doxorubicin—prostate cancer	6.03e-05	0.00025	CcSEcCtD
Tadalafil—Paraesthesia—Capecitabine—prostate cancer	6.01e-05	0.00025	CcSEcCtD
Tadalafil—Urinary tract disorder—Doxorubicin—prostate cancer	6e-05	0.000249	CcSEcCtD
Tadalafil—Oedema peripheral—Doxorubicin—prostate cancer	5.98e-05	0.000249	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Docetaxel—prostate cancer	5.97e-05	0.000248	CcSEcCtD
Tadalafil—Asthenia—Etoposide—prostate cancer	5.97e-05	0.000248	CcSEcCtD
Tadalafil—Connective tissue disorder—Doxorubicin—prostate cancer	5.97e-05	0.000248	CcSEcCtD
Tadalafil—Dyspnoea—Capecitabine—prostate cancer	5.97e-05	0.000248	CcSEcCtD
Tadalafil—Oedema—Prednisone—prostate cancer	5.96e-05	0.000248	CcSEcCtD
Tadalafil—Fatigue—Docetaxel—prostate cancer	5.96e-05	0.000248	CcSEcCtD
Tadalafil—Angiopathy—Epirubicin—prostate cancer	5.96e-05	0.000247	CcSEcCtD
Tadalafil—Urethral disorder—Doxorubicin—prostate cancer	5.95e-05	0.000247	CcSEcCtD
Tadalafil—Nausea—Mitoxantrone—prostate cancer	5.94e-05	0.000247	CcSEcCtD
Tadalafil—Immune system disorder—Epirubicin—prostate cancer	5.93e-05	0.000246	CcSEcCtD
Tadalafil—Infection—Prednisone—prostate cancer	5.92e-05	0.000246	CcSEcCtD
Tadalafil—Mediastinal disorder—Epirubicin—prostate cancer	5.92e-05	0.000246	CcSEcCtD
Tadalafil—Constipation—Docetaxel—prostate cancer	5.91e-05	0.000246	CcSEcCtD
Tadalafil—Pain—Docetaxel—prostate cancer	5.91e-05	0.000246	CcSEcCtD
Tadalafil—Dyspepsia—Capecitabine—prostate cancer	5.89e-05	0.000245	CcSEcCtD
Tadalafil—Pruritus—Etoposide—prostate cancer	5.89e-05	0.000245	CcSEcCtD
Tadalafil—Shock—Prednisone—prostate cancer	5.87e-05	0.000244	CcSEcCtD
Tadalafil—Nervous system disorder—Prednisone—prostate cancer	5.85e-05	0.000243	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.82e-05	0.000819	CbGpPWpGaD
Tadalafil—Tachycardia—Prednisone—prostate cancer	5.82e-05	0.000242	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PARP1—prostate cancer	5.8e-05	0.000816	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGFR4—prostate cancer	5.8e-05	0.000816	CbGpPWpGaD
Tadalafil—Skin disorder—Prednisone—prostate cancer	5.79e-05	0.000241	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Capecitabine—prostate cancer	5.78e-05	0.00024	CcSEcCtD
Tadalafil—Fatigue—Capecitabine—prostate cancer	5.77e-05	0.00024	CcSEcCtD
Tadalafil—Hyperhidrosis—Prednisone—prostate cancer	5.76e-05	0.000239	CcSEcCtD
Tadalafil—Mental disorder—Epirubicin—prostate cancer	5.75e-05	0.000239	CcSEcCtD
Tadalafil—Erythema multiforme—Doxorubicin—prostate cancer	5.74e-05	0.000239	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CALCA—prostate cancer	5.72e-05	0.000806	CbGpPWpGaD
Tadalafil—Pain—Capecitabine—prostate cancer	5.72e-05	0.000238	CcSEcCtD
Tadalafil—Constipation—Capecitabine—prostate cancer	5.72e-05	0.000238	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—SRC—prostate cancer	5.7e-05	0.000802	CbGpPWpGaD
Tadalafil—Diarrhoea—Etoposide—prostate cancer	5.69e-05	0.000236	CcSEcCtD
Tadalafil—Eye disorder—Doxorubicin—prostate cancer	5.68e-05	0.000236	CcSEcCtD
Tadalafil—Tinnitus—Doxorubicin—prostate cancer	5.66e-05	0.000235	CcSEcCtD
Tadalafil—Gastrointestinal pain—Docetaxel—prostate cancer	5.65e-05	0.000235	CcSEcCtD
Tadalafil—Cardiac disorder—Doxorubicin—prostate cancer	5.64e-05	0.000234	CcSEcCtD
Tadalafil—Flushing—Doxorubicin—prostate cancer	5.64e-05	0.000234	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CXCL12—prostate cancer	5.59e-05	0.000787	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.57e-05	0.000783	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—prostate cancer	5.55e-05	0.000781	CbGpPWpGaD
Tadalafil—Back pain—Epirubicin—prostate cancer	5.53e-05	0.00023	CcSEcCtD
Tadalafil—Angiopathy—Doxorubicin—prostate cancer	5.51e-05	0.000229	CcSEcCtD
Tadalafil—Dizziness—Etoposide—prostate cancer	5.5e-05	0.000229	CcSEcCtD
Tadalafil—Muscle spasms—Epirubicin—prostate cancer	5.49e-05	0.000228	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.49e-05	0.000772	CbGpPWpGaD
Tadalafil—Immune system disorder—Doxorubicin—prostate cancer	5.49e-05	0.000228	CcSEcCtD
Tadalafil—Gastrointestinal pain—Capecitabine—prostate cancer	5.47e-05	0.000227	CcSEcCtD
Tadalafil—Mediastinal disorder—Doxorubicin—prostate cancer	5.47e-05	0.000227	CcSEcCtD
Tadalafil—Abdominal pain—Docetaxel—prostate cancer	5.47e-05	0.000227	CcSEcCtD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.46e-05	0.000768	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Prednisone—prostate cancer	5.43e-05	0.000226	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.4e-05	0.000759	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.4e-05	0.000759	CbGpPWpGaD
Tadalafil—Insomnia—Prednisone—prostate cancer	5.39e-05	0.000224	CcSEcCtD
Tadalafil—Vision blurred—Epirubicin—prostate cancer	5.39e-05	0.000224	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.38e-05	0.000758	CbGpPWpGaD
Tadalafil—Paraesthesia—Prednisone—prostate cancer	5.35e-05	0.000222	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CG—prostate cancer	5.33e-05	0.00075	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.32e-05	0.000749	CbGpPWpGaD
Tadalafil—Mental disorder—Doxorubicin—prostate cancer	5.32e-05	0.000221	CcSEcCtD
Tadalafil—Urticaria—Capecitabine—prostate cancer	5.32e-05	0.000221	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.3e-05	0.000745	CbGpPWpGaD
Tadalafil—Abdominal pain—Capecitabine—prostate cancer	5.29e-05	0.00022	CcSEcCtD
Tadalafil—Vomiting—Etoposide—prostate cancer	5.29e-05	0.00022	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CASP9—prostate cancer	5.27e-05	0.000741	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.26e-05	0.00074	CbGpPWpGaD
Tadalafil—Dyspepsia—Prednisone—prostate cancer	5.25e-05	0.000218	CcSEcCtD
Tadalafil—Rash—Etoposide—prostate cancer	5.25e-05	0.000218	CcSEcCtD
Tadalafil—Dermatitis—Etoposide—prostate cancer	5.24e-05	0.000218	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—EP300—prostate cancer	5.22e-05	0.000735	CbGpPWpGaD
Tadalafil—Headache—Etoposide—prostate cancer	5.21e-05	0.000217	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.2e-05	0.000731	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CD—prostate cancer	5.16e-05	0.000726	CbGpPWpGaD
Tadalafil—Fatigue—Prednisone—prostate cancer	5.14e-05	0.000214	CcSEcCtD
Tadalafil—Vertigo—Epirubicin—prostate cancer	5.13e-05	0.000213	CcSEcCtD
Tadalafil—Syncope—Epirubicin—prostate cancer	5.12e-05	0.000213	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.12e-05	0.000721	CbGpPWpGaD
Tadalafil—Back pain—Doxorubicin—prostate cancer	5.11e-05	0.000212	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PRKCQ—prostate cancer	5.1e-05	0.000718	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NGFR—prostate cancer	5.1e-05	0.000718	CbGpPWpGaD
Tadalafil—Constipation—Prednisone—prostate cancer	5.1e-05	0.000212	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—TGFB1—prostate cancer	5.09e-05	0.000717	CbGpPWpGaD
Tadalafil—Hypersensitivity—Docetaxel—prostate cancer	5.09e-05	0.000212	CcSEcCtD
Tadalafil—Muscle spasms—Doxorubicin—prostate cancer	5.08e-05	0.000211	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—SRC—prostate cancer	5.08e-05	0.000715	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.07e-05	0.000714	CbGpPWpGaD
Tadalafil—Palpitations—Epirubicin—prostate cancer	5.05e-05	0.00021	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MAP3K7—prostate cancer	5.04e-05	0.000709	CbGpPWpGaD
Tadalafil—Loss of consciousness—Epirubicin—prostate cancer	5.02e-05	0.000209	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.02e-05	0.000706	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.02e-05	0.000706	CbGpPWpGaD
Tadalafil—Cough—Epirubicin—prostate cancer	4.99e-05	0.000207	CcSEcCtD
Tadalafil—Vision blurred—Doxorubicin—prostate cancer	4.98e-05	0.000207	CcSEcCtD
Tadalafil—Asthenia—Docetaxel—prostate cancer	4.96e-05	0.000206	CcSEcCtD
Tadalafil—Convulsion—Epirubicin—prostate cancer	4.95e-05	0.000206	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	4.95e-05	0.000696	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	4.95e-05	0.000696	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—prostate cancer	4.95e-05	0.000696	CbGpPWpGaD
Tadalafil—Nausea—Etoposide—prostate cancer	4.94e-05	0.000205	CcSEcCtD
Tadalafil—Hypertension—Epirubicin—prostate cancer	4.93e-05	0.000205	CcSEcCtD
Tadalafil—Hypersensitivity—Capecitabine—prostate cancer	4.93e-05	0.000205	CcSEcCtD
Tadalafil—Pruritus—Docetaxel—prostate cancer	4.89e-05	0.000203	CcSEcCtD
Tadalafil—Gastrointestinal pain—Prednisone—prostate cancer	4.88e-05	0.000203	CcSEcCtD
Tadalafil—Myalgia—Epirubicin—prostate cancer	4.86e-05	0.000202	CcSEcCtD
Tadalafil—Arthralgia—Epirubicin—prostate cancer	4.86e-05	0.000202	CcSEcCtD
Tadalafil—Chest pain—Epirubicin—prostate cancer	4.86e-05	0.000202	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FGF10—prostate cancer	4.85e-05	0.000682	CbGpPWpGaD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.83e-05	0.000201	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.81e-05	0.000677	CbGpPWpGaD
Tadalafil—Discomfort—Epirubicin—prostate cancer	4.81e-05	0.0002	CcSEcCtD
Tadalafil—Asthenia—Capecitabine—prostate cancer	4.8e-05	0.0002	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ADRB2—prostate cancer	4.8e-05	0.000675	CbGpPWpGaD
Tadalafil—Dry mouth—Epirubicin—prostate cancer	4.76e-05	0.000198	CcSEcCtD
Tadalafil—Vertigo—Doxorubicin—prostate cancer	4.75e-05	0.000197	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.74e-05	0.000668	CbGpPWpGaD
Tadalafil—Syncope—Doxorubicin—prostate cancer	4.74e-05	0.000197	CcSEcCtD
Tadalafil—Urticaria—Prednisone—prostate cancer	4.74e-05	0.000197	CcSEcCtD
Tadalafil—Pruritus—Capecitabine—prostate cancer	4.74e-05	0.000197	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—JAK2—prostate cancer	4.73e-05	0.000666	CbGpPWpGaD
Tadalafil—Diarrhoea—Docetaxel—prostate cancer	4.73e-05	0.000197	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—KRAS—prostate cancer	4.72e-05	0.000664	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—MAP2K1—prostate cancer	4.71e-05	0.000663	CbGpPWpGaD
Tadalafil—Abdominal pain—Prednisone—prostate cancer	4.71e-05	0.000196	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CD—prostate cancer	4.68e-05	0.000659	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VAV3—prostate cancer	4.68e-05	0.000658	CbGpPWpGaD
Tadalafil—Palpitations—Doxorubicin—prostate cancer	4.67e-05	0.000194	CcSEcCtD
Tadalafil—Oedema—Epirubicin—prostate cancer	4.66e-05	0.000194	CcSEcCtD
Tadalafil—Loss of consciousness—Doxorubicin—prostate cancer	4.65e-05	0.000193	CcSEcCtD
Tadalafil—Infection—Epirubicin—prostate cancer	4.63e-05	0.000192	CcSEcCtD
Tadalafil—Cough—Doxorubicin—prostate cancer	4.61e-05	0.000192	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TGFBR2—prostate cancer	4.61e-05	0.000649	CbGpPWpGaD
Tadalafil—Shock—Epirubicin—prostate cancer	4.59e-05	0.000191	CcSEcCtD
Tadalafil—Convulsion—Doxorubicin—prostate cancer	4.58e-05	0.00019	CcSEcCtD
Tadalafil—Diarrhoea—Capecitabine—prostate cancer	4.58e-05	0.00019	CcSEcCtD
Tadalafil—Nervous system disorder—Epirubicin—prostate cancer	4.57e-05	0.00019	CcSEcCtD
Tadalafil—Dizziness—Docetaxel—prostate cancer	4.57e-05	0.00019	CcSEcCtD
Tadalafil—Hypertension—Doxorubicin—prostate cancer	4.56e-05	0.00019	CcSEcCtD
Tadalafil—Tachycardia—Epirubicin—prostate cancer	4.55e-05	0.000189	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—TGFB1—prostate cancer	4.54e-05	0.000639	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ITPR1—prostate cancer	4.54e-05	0.000639	CbGpPWpGaD
Tadalafil—Skin disorder—Epirubicin—prostate cancer	4.53e-05	0.000188	CcSEcCtD
Tadalafil—Hyperhidrosis—Epirubicin—prostate cancer	4.51e-05	0.000187	CcSEcCtD
Tadalafil—Chest pain—Doxorubicin—prostate cancer	4.5e-05	0.000187	CcSEcCtD
Tadalafil—Myalgia—Doxorubicin—prostate cancer	4.5e-05	0.000187	CcSEcCtD
Tadalafil—Arthralgia—Doxorubicin—prostate cancer	4.5e-05	0.000187	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CB—prostate cancer	4.49e-05	0.000632	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.47e-05	0.000629	CbGpPWpGaD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.47e-05	0.000186	CcSEcCtD
Tadalafil—Discomfort—Doxorubicin—prostate cancer	4.45e-05	0.000185	CcSEcCtD
Tadalafil—Dizziness—Capecitabine—prostate cancer	4.43e-05	0.000184	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.42e-05	0.000622	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.41e-05	0.000621	CbGpPWpGaD
Tadalafil—Dry mouth—Doxorubicin—prostate cancer	4.4e-05	0.000183	CcSEcCtD
Tadalafil—Vomiting—Docetaxel—prostate cancer	4.4e-05	0.000183	CcSEcCtD
Tadalafil—Hypersensitivity—Prednisone—prostate cancer	4.39e-05	0.000183	CcSEcCtD
Tadalafil—Rash—Docetaxel—prostate cancer	4.36e-05	0.000181	CcSEcCtD
Tadalafil—Hypotension—Epirubicin—prostate cancer	4.36e-05	0.000181	CcSEcCtD
Tadalafil—Dermatitis—Docetaxel—prostate cancer	4.36e-05	0.000181	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IGF1R—prostate cancer	4.34e-05	0.000611	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CA—prostate cancer	4.34e-05	0.00061	CbGpPWpGaD
Tadalafil—Headache—Docetaxel—prostate cancer	4.33e-05	0.00018	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—CXCL8—prostate cancer	4.32e-05	0.000608	CbGpPWpGaD
Tadalafil—Oedema—Doxorubicin—prostate cancer	4.31e-05	0.000179	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—JAK2—prostate cancer	4.3e-05	0.000605	CbGpPWpGaD
Tadalafil—Infection—Doxorubicin—prostate cancer	4.29e-05	0.000178	CcSEcCtD
Tadalafil—Asthenia—Prednisone—prostate cancer	4.28e-05	0.000178	CcSEcCtD
Tadalafil—Vomiting—Capecitabine—prostate cancer	4.26e-05	0.000177	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.25e-05	0.000177	CcSEcCtD
Tadalafil—Shock—Doxorubicin—prostate cancer	4.25e-05	0.000176	CcSEcCtD
Tadalafil—Nervous system disorder—Doxorubicin—prostate cancer	4.23e-05	0.000176	CcSEcCtD
Tadalafil—Rash—Capecitabine—prostate cancer	4.22e-05	0.000175	CcSEcCtD
Tadalafil—Pruritus—Prednisone—prostate cancer	4.22e-05	0.000175	CcSEcCtD
Tadalafil—Insomnia—Epirubicin—prostate cancer	4.22e-05	0.000175	CcSEcCtD
Tadalafil—Dermatitis—Capecitabine—prostate cancer	4.22e-05	0.000175	CcSEcCtD
Tadalafil—Tachycardia—Doxorubicin—prostate cancer	4.21e-05	0.000175	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.21e-05	0.000592	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—KRAS—prostate cancer	4.21e-05	0.000592	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TP53—prostate cancer	4.19e-05	0.00059	CbGpPWpGaD
Tadalafil—Headache—Capecitabine—prostate cancer	4.19e-05	0.000174	CcSEcCtD
Tadalafil—Skin disorder—Doxorubicin—prostate cancer	4.19e-05	0.000174	CcSEcCtD
Tadalafil—Paraesthesia—Epirubicin—prostate cancer	4.19e-05	0.000174	CcSEcCtD
Tadalafil—Hyperhidrosis—Doxorubicin—prostate cancer	4.17e-05	0.000173	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.16e-05	0.000586	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LPL—prostate cancer	4.16e-05	0.000585	CbGpPWpGaD
Tadalafil—Dyspnoea—Epirubicin—prostate cancer	4.16e-05	0.000173	CcSEcCtD
Tadalafil—Somnolence—Epirubicin—prostate cancer	4.15e-05	0.000172	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—IL2—prostate cancer	4.13e-05	0.000581	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDGFRB—prostate cancer	4.12e-05	0.00058	CbGpPWpGaD
Tadalafil—Nausea—Docetaxel—prostate cancer	4.11e-05	0.000171	CcSEcCtD
Tadalafil—Dyspepsia—Epirubicin—prostate cancer	4.11e-05	0.000171	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CB—prostate cancer	4.08e-05	0.000574	CbGpPWpGaD
Tadalafil—Diarrhoea—Prednisone—prostate cancer	4.08e-05	0.000169	CcSEcCtD
Tadalafil—Hypotension—Doxorubicin—prostate cancer	4.03e-05	0.000168	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Epirubicin—prostate cancer	4.03e-05	0.000167	CcSEcCtD
Tadalafil—Fatigue—Epirubicin—prostate cancer	4.02e-05	0.000167	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ITGB3—prostate cancer	4.02e-05	0.000565	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.01e-05	0.000564	CbGpPWpGaD
Tadalafil—Pain—Epirubicin—prostate cancer	3.99e-05	0.000166	CcSEcCtD
Tadalafil—Constipation—Epirubicin—prostate cancer	3.99e-05	0.000166	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	3.99e-05	0.000561	CbGpPWpGaD
Tadalafil—Nausea—Capecitabine—prostate cancer	3.98e-05	0.000165	CcSEcCtD
Tadalafil—Dizziness—Prednisone—prostate cancer	3.94e-05	0.000164	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.93e-05	0.000553	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.93e-05	0.000163	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—CXCL8—prostate cancer	3.92e-05	0.000552	CbGpPWpGaD
Tadalafil—Insomnia—Doxorubicin—prostate cancer	3.9e-05	0.000162	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ERBB3—prostate cancer	3.9e-05	0.000548	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGFR2—prostate cancer	3.89e-05	0.000547	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.89e-05	0.000547	CbGpPWpGaD
Tadalafil—Paraesthesia—Doxorubicin—prostate cancer	3.87e-05	0.000161	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PIK3CA—prostate cancer	3.86e-05	0.000544	CbGpPWpGaD
Tadalafil—Dyspnoea—Doxorubicin—prostate cancer	3.85e-05	0.00016	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.85e-05	0.000541	CbGpPWpGaD
Tadalafil—Somnolence—Doxorubicin—prostate cancer	3.84e-05	0.000159	CcSEcCtD
Tadalafil—Gastrointestinal pain—Epirubicin—prostate cancer	3.81e-05	0.000158	CcSEcCtD
Tadalafil—Dyspepsia—Doxorubicin—prostate cancer	3.8e-05	0.000158	CcSEcCtD
Tadalafil—Vomiting—Prednisone—prostate cancer	3.79e-05	0.000157	CcSEcCtD
Tadalafil—Rash—Prednisone—prostate cancer	3.76e-05	0.000156	CcSEcCtD
Tadalafil—Dermatitis—Prednisone—prostate cancer	3.76e-05	0.000156	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—IL2—prostate cancer	3.75e-05	0.000527	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TP53—prostate cancer	3.74e-05	0.000526	CbGpPWpGaD
Tadalafil—Headache—Prednisone—prostate cancer	3.74e-05	0.000155	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TERT—prostate cancer	3.73e-05	0.000526	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.73e-05	0.000155	CcSEcCtD
Tadalafil—Fatigue—Doxorubicin—prostate cancer	3.72e-05	0.000155	CcSEcCtD
Tadalafil—Urticaria—Epirubicin—prostate cancer	3.7e-05	0.000154	CcSEcCtD
Tadalafil—Pain—Doxorubicin—prostate cancer	3.69e-05	0.000153	CcSEcCtD
Tadalafil—Constipation—Doxorubicin—prostate cancer	3.69e-05	0.000153	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.69e-05	0.000519	CbGpPWpGaD
Tadalafil—Abdominal pain—Epirubicin—prostate cancer	3.69e-05	0.000153	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.68e-05	0.000518	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.63e-05	0.000511	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HIF1A—prostate cancer	3.57e-05	0.000503	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT1—prostate cancer	3.54e-05	0.000498	CbGpPWpGaD
Tadalafil—Nausea—Prednisone—prostate cancer	3.54e-05	0.000147	CcSEcCtD
Tadalafil—Gastrointestinal pain—Doxorubicin—prostate cancer	3.53e-05	0.000147	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.51e-05	0.000494	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LEP—prostate cancer	3.49e-05	0.000491	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CAV1—prostate cancer	3.45e-05	0.000486	CbGpPWpGaD
Tadalafil—Hypersensitivity—Epirubicin—prostate cancer	3.44e-05	0.000143	CcSEcCtD
Tadalafil—Urticaria—Doxorubicin—prostate cancer	3.43e-05	0.000142	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KDR—prostate cancer	3.42e-05	0.000481	CbGpPWpGaD
Tadalafil—Abdominal pain—Doxorubicin—prostate cancer	3.41e-05	0.000142	CcSEcCtD
Tadalafil—Asthenia—Epirubicin—prostate cancer	3.35e-05	0.000139	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ESR1—prostate cancer	3.33e-05	0.000468	CbGpPWpGaD
Tadalafil—Pruritus—Epirubicin—prostate cancer	3.3e-05	0.000137	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.27e-05	0.00046	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—BAD—prostate cancer	3.25e-05	0.000457	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.23e-05	0.000454	CbGpPWpGaD
Tadalafil—Diarrhoea—Epirubicin—prostate cancer	3.19e-05	0.000133	CcSEcCtD
Tadalafil—Hypersensitivity—Doxorubicin—prostate cancer	3.18e-05	0.000132	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—AKT1—prostate cancer	3.16e-05	0.000444	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APC—prostate cancer	3.15e-05	0.000443	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CG—prostate cancer	3.15e-05	0.000443	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IRS1—prostate cancer	3.11e-05	0.000438	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EGF—prostate cancer	3.11e-05	0.000438	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.1e-05	0.000436	CbGpPWpGaD
Tadalafil—Asthenia—Doxorubicin—prostate cancer	3.1e-05	0.000129	CcSEcCtD
Tadalafil—Dizziness—Epirubicin—prostate cancer	3.08e-05	0.000128	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.06e-05	0.00043	CbGpPWpGaD
Tadalafil—Pruritus—Doxorubicin—prostate cancer	3.05e-05	0.000127	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—GSK3B—prostate cancer	3.02e-05	0.000425	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GGT1—prostate cancer	3e-05	0.000422	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—INS—prostate cancer	2.98e-05	0.000419	CbGpPWpGaD
Tadalafil—Vomiting—Epirubicin—prostate cancer	2.97e-05	0.000123	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.96e-05	0.000416	CbGpPWpGaD
Tadalafil—Diarrhoea—Doxorubicin—prostate cancer	2.95e-05	0.000123	CcSEcCtD
Tadalafil—Rash—Epirubicin—prostate cancer	2.94e-05	0.000122	CcSEcCtD
Tadalafil—Dermatitis—Epirubicin—prostate cancer	2.94e-05	0.000122	CcSEcCtD
Tadalafil—Headache—Epirubicin—prostate cancer	2.92e-05	0.000121	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CREBBP—prostate cancer	2.92e-05	0.000411	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.91e-05	0.00041	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF1—prostate cancer	2.88e-05	0.000405	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.87e-05	0.000404	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—EGFR—prostate cancer	2.87e-05	0.000403	CbGpPWpGaD
Tadalafil—Dizziness—Doxorubicin—prostate cancer	2.85e-05	0.000119	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.81e-05	0.000396	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAP2K1—prostate cancer	2.78e-05	0.000392	CbGpPWpGaD
Tadalafil—Nausea—Epirubicin—prostate cancer	2.77e-05	0.000115	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PIK3CD—prostate cancer	2.77e-05	0.000389	CbGpPWpGaD
Tadalafil—Vomiting—Doxorubicin—prostate cancer	2.74e-05	0.000114	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CA—prostate cancer	2.74e-05	0.000386	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SERPINE1—prostate cancer	2.74e-05	0.000385	CbGpPWpGaD
Tadalafil—Rash—Doxorubicin—prostate cancer	2.72e-05	0.000113	CcSEcCtD
Tadalafil—Dermatitis—Doxorubicin—prostate cancer	2.72e-05	0.000113	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—COMT—prostate cancer	2.71e-05	0.000381	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—KRAS—prostate cancer	2.71e-05	0.000381	CbGpPWpGaD
Tadalafil—Headache—Doxorubicin—prostate cancer	2.7e-05	0.000112	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.7e-05	0.000379	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.67e-05	0.000376	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.66e-05	0.000374	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGF2—prostate cancer	2.65e-05	0.000373	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NOS3—prostate cancer	2.61e-05	0.000368	CbGpPWpGaD
Tadalafil—Nausea—Doxorubicin—prostate cancer	2.56e-05	0.000106	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—JAK2—prostate cancer	2.54e-05	0.000357	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CA—prostate cancer	2.49e-05	0.00035	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.48e-05	0.000349	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MDM2—prostate cancer	2.48e-05	0.000349	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.44e-05	0.000344	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ERBB2—prostate cancer	2.44e-05	0.000344	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CB—prostate cancer	2.41e-05	0.000339	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.35e-05	0.000331	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HAO1—prostate cancer	2.32e-05	0.000326	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.32e-05	0.000326	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CXCL8—prostate cancer	2.32e-05	0.000326	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1B—prostate cancer	2.26e-05	0.000318	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKT1—prostate cancer	2.24e-05	0.000315	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CASP3—prostate cancer	2.22e-05	0.000312	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL2—prostate cancer	2.21e-05	0.000312	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—prostate cancer	2.2e-05	0.00031	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCND1—prostate cancer	2.16e-05	0.000304	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNB1—prostate cancer	2.14e-05	0.000301	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP9—prostate cancer	2.1e-05	0.000295	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1A—prostate cancer	2.09e-05	0.000294	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTEN—prostate cancer	2.08e-05	0.000293	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT1—prostate cancer	2.03e-05	0.000286	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EP300—prostate cancer	1.99e-05	0.00028	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SRC—prostate cancer	1.93e-05	0.000272	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CBR1—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CSAD—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GRHL1—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TST—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ADI1—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PSAT1—prostate cancer	1.89e-05	0.000266	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—prostate cancer	1.88e-05	0.000265	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT3—prostate cancer	1.86e-05	0.000262	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.76e-05	0.000247	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CKMT2—prostate cancer	1.76e-05	0.000247	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.76e-05	0.000247	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GRHPR—prostate cancer	1.76e-05	0.000247	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MYC—prostate cancer	1.73e-05	0.000244	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TGFB1—prostate cancer	1.73e-05	0.000243	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EGFR—prostate cancer	1.69e-05	0.000238	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PGAM2—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—RFK—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAGLU—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AOX1—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM3—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.65e-05	0.000232	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KRAS—prostate cancer	1.6e-05	0.000225	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AMACR—prostate cancer	1.57e-05	0.00022	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.57e-05	0.00022	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.57e-05	0.00022	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—DEGS1—prostate cancer	1.57e-05	0.00022	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAT1—prostate cancer	1.57e-05	0.00022	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.49e-05	0.00021	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CA—prostate cancer	1.47e-05	0.000207	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TP53—prostate cancer	1.42e-05	0.0002	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HPGD—prostate cancer	1.33e-05	0.000187	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.33e-05	0.000187	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—prostate cancer	1.3e-05	0.000183	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.25e-05	0.000176	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.22e-05	0.000171	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTAP—prostate cancer	1.22e-05	0.000171	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT1—prostate cancer	1.2e-05	0.000169	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.19e-05	0.000167	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.19e-05	0.000167	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACSL4—prostate cancer	1.13e-05	0.000159	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.13e-05	0.000159	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PHGDH—prostate cancer	1.09e-05	0.000153	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UMPS—prostate cancer	1.09e-05	0.000153	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ARG2—prostate cancer	1.09e-05	0.000153	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LDHB—prostate cancer	1.06e-05	0.00015	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.04e-05	0.000147	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PDHA1—prostate cancer	1.01e-05	0.000142	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UCP3—prostate cancer	1.01e-05	0.000142	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA3—prostate cancer	1.01e-05	0.000142	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TCN2—prostate cancer	1.01e-05	0.000142	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD3B1—prostate cancer	9.63e-06	0.000135	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC22A3—prostate cancer	9.63e-06	0.000135	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.23e-06	0.00013	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA4—prostate cancer	9.23e-06	0.00013	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA2—prostate cancer	9e-06	0.000127	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCG5—prostate cancer	8.88e-06	0.000125	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.88e-06	0.000125	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA1—prostate cancer	8.68e-06	0.000122	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTO1—prostate cancer	8.58e-06	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAT2—prostate cancer	8.58e-06	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.58e-06	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PLCB2—prostate cancer	8.23e-06	0.000116	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.23e-06	0.000116	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LRP2—prostate cancer	8.23e-06	0.000116	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—P4HB—prostate cancer	8.07e-06	0.000114	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.85e-06	0.00011	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.65e-06	0.000108	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MED12—prostate cancer	7.52e-06	0.000106	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GNG5—prostate cancer	7.47e-06	0.000105	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA3—prostate cancer	7.19e-06	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HPGDS—prostate cancer	6.86e-06	9.65e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.82e-06	9.59e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACHE—prostate cancer	6.65e-06	9.36e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTT1—prostate cancer	6.65e-06	9.36e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.58e-06	9.25e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.4e-06	9e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PRKACB—prostate cancer	6.36e-06	8.96e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.3e-06	8.86e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA2—prostate cancer	6e-06	8.45e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.73e-06	8.06e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.59e-06	7.87e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NQO1—prostate cancer	5.53e-06	7.78e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TH—prostate cancer	5.45e-06	7.67e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.3e-06	7.46e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GGT1—prostate cancer	5.13e-06	7.22e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA1—prostate cancer	5.06e-06	7.12e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.98e-06	7.01e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—RXRA—prostate cancer	4.81e-06	6.77e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—COMT—prostate cancer	4.63e-06	6.52e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTP1—prostate cancer	4.61e-06	6.49e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ITPR1—prostate cancer	4.54e-06	6.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TYMS—prostate cancer	4.29e-06	6.03e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—prostate cancer	4.24e-06	5.96e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LPL—prostate cancer	4.16e-06	5.85e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.02e-06	5.65e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ERCC2—prostate cancer	3.98e-06	5.61e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—prostate cancer	3.75e-06	5.27e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARA—prostate cancer	3.67e-06	5.17e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CAV1—prostate cancer	3.45e-06	4.86e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.15e-06	4.43e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—INS—prostate cancer	2.98e-06	4.19e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CREBBP—prostate cancer	2.92e-06	4.11e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.77e-06	3.89e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NOS3—prostate cancer	2.61e-06	3.68e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.41e-06	3.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS2—prostate cancer	2.39e-06	3.36e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTEN—prostate cancer	2.08e-06	2.93e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—EP300—prostate cancer	1.99e-06	2.8e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.47e-06	2.07e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKT1—prostate cancer	1.2e-06	1.69e-05	CbGpPWpGaD
